



(12) Translation of
European patent specification

(11) NO/EP 3150586 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 277/28 (2006.01)
A61K 31/427 (2006.01)
A61P 31/12 (2006.01)
C07D 417/14 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2020.03.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.01.08
(86)	European Application Nr.	16180589.0
(86)	European Filing Date	2008.02.22
(87)	The European Application's Publication Date	2017.04.05
(30)	Priority	2007.02.23, US, 903228 P 2007.07.06, US, 958716 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL ; BA ; MK ; RS
(62)	Divided application	EP2487161, 2008.02.22
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	Desai, Manoj, C., 1975 Mohawk Drive, Pleasant Hill, CA 94523, USA Hong, Allen, Y., 4957 Williams Rd., San Jose, CA 95129, USA Hui, Hon, C., 853 Woodside Way, 229, San Mateo, CA 94401, USA Liu, Hongtao, 10320 Orange Avenue, Cupertino, CA 95014, USA Vivian, Randall, W., 1430 Via Vista, San Mateo, CA 94404, USA Xu, Lianhong, 970 Blair Court, Palo Alto, CA 94303, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
(56)	References Cited:	EP-B- 1 183 026 WO-A1-97/01349 WO-A-2008/010921

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel IIBb



(IIBb)

5 eller et farmasøytisk akseptabelt salt eller solvat derav, i kombinasjon med ett eller flere ytterligere terapeutiske midler valgt fra gruppen bestående av HIV-proteasehemmende-forbindelser, HIV ikke-nukleosidinhibitorer av revers-transkriptase, HIV-nukleosidinhibitorer av revers-transkriptase, HIV-nukleotidinhibitorer av revers-transkriptase, HIV-integrase-inhibitorer, gp41-inhibitorer, CXCR4-inhibitorer, gp120-inhibitorer, G6PD- og NADH-oksidasel-
 10 inhibitorer, CCR5-inhibitorer, andre medisiner for behandling av HIV, og blandinger derav,

til anvendelse i behandling av en HIV-infeksjon.

2. Kombinasjon for anvendelse ifølge krav 1, omfattende mer enn ett
 15 ytterligere terapeutisk middel valgt fra gruppen bestående av
 amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35, AG 1859, capravirin, emivirin,
 20 delaviridin, efavirenz, nevirapin, (+) calanolid A, etravirin, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpiviren), efavirenz, BILR 355 BS, VRX 840773, UK-453061, RDEA806, zidovudin, emtricitabin, didanosin, stavudin, zalcitabin, lamivudin, abacavir, amdoxovir, elvucitabin, alovudin, MIV-210, racivir (±-FTC), D-d4FC, fosfazid, fozivudin tidoxil, apricitibin (AVX754), amdoxovir, KP-

1461, fosaltudin tidoxil (tidligere HDP 99.0003), curcumin, derivater av curcumin, chikorsyre, derivater av chikorsyre, 3,5- kaffoylkininsyre, derivater av 3,5-di-kaffoylkininsyre, aurintrikarboksylysyre, derivater av aurintrikarboksylysyre, koffeinsyrephenetylester, derivater av koffeinsyrephenetylester, tyrfostin, derivater av tyrfostin, quercetin, derivater av quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK-2048, BA 011, enfuvirtid, sifuvirtid, FB006M, TRI-1144, AMD-070, en inngangsinhibitor, SP01A, BMS-488043, BlockAide/CR, en G6PD- og NADH- oksidaseinhibitor, immunitin, aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), CCR5mAb004, BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 og PA-1050040 (PA-040).